The Food and Drug Administration (USFDA) is not satisfied with the quality of drugs produced by Ranbaxy. The agency has issued two letters to Indian drug major, warning it about the drug quality. The agency has raised questions on the quality of more than 30 generic drugs. The company is producing these drugs at its Paonta Sahib and Dewas plants.

The director of the USFDA's drug compliance office, Deborah M. Autor said that these drugs are, though not harmful, but violations in manufacturing process can produce defective products. The agency is blocking the medicines produced at Paonta Sahib and Dewas plants. The drug tests for other plants are not being banned. Autor maintained that at present its just a warning to Ranbaxy that its entry in US market may be banned in case of further violations.

Indian drug maker, Ranbaxy is under agency’s vigil since 2006. The company has 11 plants in India and other countries and is a leading drug supplier in the US market. Its brand product ‘Revital’ is still popular in the market.